Since the Reimbursement Act came into effect, patients have been fighting to access treatment using innovative therapies. Frequently, the only hope they have is a targeted import procedure, which can be used to import medicines unavailable in Poland for the needs of individual patients. The targeted import procedure enables treatment to be provided with medicines whose price is generally beyond patients’ financial capacity.
The judgment passed on 9 February 2016 by the VAC in Warsaw could lead to a change favourable for patients in how reimbursement regulations are interpreted. In this judgment the VAC in Warsaw upheld the position we put forward in the appeal against the Minister of Health’s decision to refuse reimbursement for medicine for a boy suffering from muscular dystrophy. The boy’s condition required urgent treatment with a medicine currently unavailable in Poland.